Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (21-30 of 179) with videos related to

Pageof 18
Sort By:
American Journal of Hematology|April 5, 2012
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemiaElias J Jabbour, Hagop Kantarjian, Lina Eliasson, et al.
Haematologica|December 3, 2011
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformationDragana Milojkovic, Amr Ibrahim, Alistair Reid, et al.
Statistics in Medicine|April 20, 2026
BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing ChangesCheng-Han Yang, Peter F Thall, David Marin, et al.
Haematologica|July 28, 2006
Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemiaJolanta B Perz, Jamshid S Khorashad, David Marin, et al.
Journal of Chemical Ecology|September 27, 2007
Interactions of Bacillus mojavensis and Fusarium verticillioides with a benzoxazolinone (BOA) and its transformation product, APOCharles W Bacon, Dorothy M Hinton, Anthony E Glenn, et al.
Medicines (Basel, Switzerland)|February 20, 2026
Pharmacotherapy for Alcohol Craving Reduction: Efficacy of Short-Term Treatments in Alcohol Use DisorderMatheus Cheibub David Marin, Maria Olivia Pozzolo Pedro, Giuliana Perrotte, et al.
Haematologica|February 27, 2003
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylateDavid Marin, Sarah Marktel, Nicola Foot, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|February 9, 2005
Optimal path to epigenetic switchingDavid Marin Roma, Ruadhan A O'Flanagan, Andrei E Ruckenstein, et al.
Blood|October 6, 2006
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant alleleMona Anand, Jamshid Khorashad, David Marin, et al.
British Journal of Haematology|November 18, 2003
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remissionMark W Drummond, David Marin, Richard E Clark, et al.
Pageof 18

Showing results (21-30 of 179) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|April 5, 2012
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemiaElias J Jabbour, Hagop Kantarjian, Lina Eliasson, et al.
Haematologica|December 3, 2011
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformationDragana Milojkovic, Amr Ibrahim, Alistair Reid, et al.
Statistics in Medicine|April 20, 2026
BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing ChangesCheng-Han Yang, Peter F Thall, David Marin, et al.
Haematologica|July 28, 2006
Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemiaJolanta B Perz, Jamshid S Khorashad, David Marin, et al.
Journal of Chemical Ecology|September 27, 2007
Interactions of Bacillus mojavensis and Fusarium verticillioides with a benzoxazolinone (BOA) and its transformation product, APOCharles W Bacon, Dorothy M Hinton, Anthony E Glenn, et al.
Medicines (Basel, Switzerland)|February 20, 2026
Pharmacotherapy for Alcohol Craving Reduction: Efficacy of Short-Term Treatments in Alcohol Use DisorderMatheus Cheibub David Marin, Maria Olivia Pozzolo Pedro, Giuliana Perrotte, et al.
Haematologica|February 27, 2003
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylateDavid Marin, Sarah Marktel, Nicola Foot, et al.
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|February 9, 2005
Optimal path to epigenetic switchingDavid Marin Roma, Ruadhan A O'Flanagan, Andrei E Ruckenstein, et al.
Blood|October 6, 2006
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant alleleMona Anand, Jamshid Khorashad, David Marin, et al.
British Journal of Haematology|November 18, 2003
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remissionMark W Drummond, David Marin, Richard E Clark, et al.
Pageof 18